ATE524472T1 - SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS - Google Patents

SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS

Info

Publication number
ATE524472T1
ATE524472T1 AT08717594T AT08717594T ATE524472T1 AT E524472 T1 ATE524472 T1 AT E524472T1 AT 08717594 T AT08717594 T AT 08717594T AT 08717594 T AT08717594 T AT 08717594T AT E524472 T1 ATE524472 T1 AT E524472T1
Authority
AT
Austria
Prior art keywords
substituted
pyrimidodiazepines
plk1 inhibitors
plk1
inhibitors
Prior art date
Application number
AT08717594T
Other languages
German (de)
Inventor
Jianping Cai
Shaoqing Chen
Xin-Jie Chu
Kang Le
Kin-Chun Thomas Luk
Peter Michael Wovkulich
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE524472(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE524472T1 publication Critical patent/ATE524472T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT08717594T 2007-03-22 2008-03-11 SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS ATE524472T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
PCT/EP2008/052847 WO2008113711A1 (en) 2007-03-22 2008-03-11 Substituted pyrimidodiazepines useful as plk1 inhibitors

Publications (1)

Publication Number Publication Date
ATE524472T1 true ATE524472T1 (en) 2011-09-15

Family

ID=39415299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08717594T ATE524472T1 (en) 2007-03-22 2008-03-11 SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS

Country Status (24)

Country Link
US (1) US7517873B2 (en)
EP (1) EP2139892B1 (en)
JP (1) JP5087640B2 (en)
KR (1) KR101157848B1 (en)
CN (2) CN101636399B (en)
AR (1) AR065794A1 (en)
AT (1) ATE524472T1 (en)
AU (1) AU2008228303B2 (en)
BR (1) BRPI0809088A2 (en)
CA (1) CA2680757A1 (en)
CL (1) CL2008000785A1 (en)
CY (1) CY1112102T1 (en)
DK (1) DK2139892T3 (en)
ES (1) ES2371832T3 (en)
HK (1) HK1139936A1 (en)
HR (1) HRP20110807T1 (en)
IL (1) IL200617A (en)
MX (1) MX2009010034A (en)
PE (1) PE20120495A1 (en)
PL (1) PL2139892T3 (en)
PT (1) PT2139892E (en)
SI (1) SI2139892T1 (en)
TW (1) TWI363629B (en)
WO (1) WO2008113711A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190849B1 (en) * 2007-08-15 2013-11-20 Vertex Pharmceuticals Incorporated 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
KR20140097440A (en) * 2007-09-25 2014-08-06 다케다 야쿠힌 고교 가부시키가이샤 Polo-like kinase inhibitors
JP5410432B2 (en) * 2007-09-28 2014-02-05 サイクラセル リミテッド Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (en) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
TW201639852A (en) 2008-12-09 2016-11-16 吉李德科學股份有限公司 Intermediate compounds for preparation of compounds useful as modulators of toll-like receptors
EP3255047B1 (en) 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
CN104940202B (en) 2009-06-17 2018-10-16 沃泰克斯药物股份有限公司 Inhibitors of influenza viruses replication
PL2477987T3 (en) 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulators of toll-like receptors
CN103492381A (en) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 Inhibitors of influenza viruses replication
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
US9676792B2 (en) * 2013-03-15 2017-06-13 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
RU2016105108A (en) 2013-07-25 2017-08-30 Дана-Фарбер Кэнсер Инститьют, Инк. TRANSCRIPTION FACTOR INHIBITORS AND THEIR APPLICATION
TWI652014B (en) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 Heterocyclic substituted bicycloazole insecticide
PL3068782T3 (en) 2013-11-13 2018-12-31 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
NZ719729A (en) 2013-11-13 2022-04-29 Vertex Pharma Inhibitors of influenza viruses replication
KR20160115953A (en) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP2017504651A (en) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Use of diazepan derivatives
MX2017000026A (en) 2014-07-11 2017-05-01 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv.
BR112017002369A2 (en) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc diazepan derivatives and uses thereof
SI3194401T1 (en) 2014-09-16 2020-12-31 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
ES2845205T3 (en) 2014-09-16 2021-07-26 Gilead Sciences Inc Methods for preparing Toll-like receptor modulators
JP6704416B2 (en) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Methods for preparing inhibitors of influenza virus replication
MA42422A (en) 2015-05-13 2018-05-23 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
SG10202007099TA (en) 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Acetamide thienotriazoldiazepines and uses thereof
JP2018526421A (en) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Cyanothienotriazolodiazepines and their use
EP3380100A4 (en) 2015-11-25 2019-10-02 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
CA3020172A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
US20220378919A1 (en) * 2019-09-27 2022-12-01 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (en) * 2020-12-31 2022-07-07 (주) 업테라 Pyrimidodiazepine derivative as selective plk1 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
WO2003020722A1 (en) * 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
KR20080095902A (en) * 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 Dihydrodiazepines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
CY1112102T1 (en) 2015-11-04
US20080234255A1 (en) 2008-09-25
CN101636399A (en) 2010-01-27
PE20120495A1 (en) 2012-05-12
HK1139936A1 (en) 2010-09-30
KR20090119913A (en) 2009-11-20
TW200843781A (en) 2008-11-16
DK2139892T3 (en) 2011-12-12
CN102746175B (en) 2014-01-15
TWI363629B (en) 2012-05-11
WO2008113711A1 (en) 2008-09-25
EP2139892B1 (en) 2011-09-14
BRPI0809088A2 (en) 2014-09-09
CA2680757A1 (en) 2008-09-25
AU2008228303A1 (en) 2008-09-25
IL200617A (en) 2014-02-27
CN101636399B (en) 2012-04-18
CN102746175A (en) 2012-10-24
AR065794A1 (en) 2009-07-01
JP2010521514A (en) 2010-06-24
CL2008000785A1 (en) 2009-03-27
EP2139892A1 (en) 2010-01-06
KR101157848B1 (en) 2012-07-11
SI2139892T1 (en) 2011-12-30
JP5087640B2 (en) 2012-12-05
PL2139892T3 (en) 2012-03-30
HRP20110807T1 (en) 2011-12-31
PT2139892E (en) 2011-11-21
IL200617A0 (en) 2010-05-17
US7517873B2 (en) 2009-04-14
AU2008228303B2 (en) 2012-04-19
ES2371832T3 (en) 2012-01-10
MX2009010034A (en) 2009-10-12

Similar Documents

Publication Publication Date Title
ATE524472T1 (en) SUBSTITUTED PYRIMIDODIAZEPINES SUBSTITUTED AS PLK1 INHIBITORS
CY2020023I2 (en) BETA-LACTAMAS INHIBITORS
CY2017016I1 (en) PROTEASOMY INHIBITORS
ATE522535T1 (en) PYRROLOTRIAZINE KINASE INHIBITORS
ATE502948T1 (en) SUBSTITUTED BICYCLOLACTAM COMPOUNDS
DK2288375T3 (en) PEGYLED INSULIN-LISPRO COMPOUNDS
BRPI0920707A2 (en) compounds
BRPI0813500A2 (en) ANTIVIAL COMPOUNDS
DK2242759T3 (en) compounds
BRPI0821086A2 (en) INSECTICATED COMPOUNDS
BRPI0811264A2 (en) COMPOUNDS
BRPI0922880A2 (en) kinase inhibitor compounds
DK2323972T3 (en) C7-FLUOR-SUBSTITUTED TETRACYLIN COMPOUNDS
DK2297162T3 (en) compounds
BRPI0918564A2 (en) inhibitors
BRPI0814424A2 (en) HYPEROCYCLE COMPOUNDS
UY3776Q (en) WRISTWATCH
BRPI0916432A2 (en) compounds
BRPI0809996A2 (en) COMPOUNDS
BRPI0815181A2 (en) COMPOUNDS
DE112008002921A5 (en) chuck
DK2206698T3 (en) Ethynylindole compounds
BRPI0922152A2 (en) Compounds
BRPI0814613A2 (en) COMPOUNDS
BRPI0922134A2 (en) Compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2139892

Country of ref document: EP